Jack has a degree in Medical Genetics from the University of Leicester.View full profile Jack has a degree in Medical Genetics from the University of Leicester. As the coronavirus pandemic continues ...

Scientists and public health experts built the COVID-19 pandemic response on years of experience navigating infectious disease outbreaks. Although lateral flow immunoassays have been central to ...

CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased ...

In a recent review published in Nature Reviews Bioengineering, researchers assessed the changing landscape of lateral flow tests (LFTs), and the development of next-generation LFTs based on lessons ...

CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has received the first data for its SARS-CoV-2 rapid ...

In our best practices blog, we explore how lateral flow assay design affects test performance. Read on to gain a deeper understanding of the development process, enabling you to streamline the ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

An artificial intelligence app to read COVID-19 lateral flow tests helped to reduce false results in a new trial out today. Published in Cell Reports Medicine, a team of researchers from the ...